138 related articles for article (PubMed ID: 9331017)
21. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
Ohma KP; Milon H; Valnes K
Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
[TBL] [Abstract][Full Text] [Related]
22. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
Andersson OK
Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide.
Plouin PF
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S65-6. PubMed ID: 9331012
[No Abstract] [Full Text] [Related]
24. Candesartan cilexetil. A review of its use in essential hypertension.
McClellan KJ; Goa KL
Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
[TBL] [Abstract][Full Text] [Related]
25. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.
Philipp T; Letzel H; Arens HJ
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S67-8. PubMed ID: 9331013
[No Abstract] [Full Text] [Related]
26. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
[TBL] [Abstract][Full Text] [Related]
27. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
Andersson OK; Neldam S
Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
[TBL] [Abstract][Full Text] [Related]
28. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
29. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Asmar R; Porcellati C; Dusing R
Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
[TBL] [Abstract][Full Text] [Related]
30. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
31. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
32. Reducing cardiovascular morbidity and mortality in the elderly.
Trenkwalder P
Blood Press Suppl; 2000; 1():40-3. PubMed ID: 11059636
[TBL] [Abstract][Full Text] [Related]
33. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
[TBL] [Abstract][Full Text] [Related]
34. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
[TBL] [Abstract][Full Text] [Related]
35. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Kaku K; Enya K; Sugiura K; Totsuka N
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():73-84. PubMed ID: 22106979
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.
MacGregor GA; Viskoper JR; Antonios TF; He FJ
Hypertension; 2000 Sep; 36(3):454-60. PubMed ID: 10988281
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
Association of Black Cardiologists (ABC) Candesartan Study Group
Heart Dis; 2000; 2(6):392-9. PubMed ID: 11728289
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
40. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
